blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3286184

EP3286184 - COMPOUNDS FOR TREATING RAC-GTPASE MEDIATED DISORDER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.02.2021
Database last updated on 28.03.2026
FormerThe patent has been granted
Status updated on  21.02.2020
FormerGrant of patent is intended
Status updated on  16.10.2019
FormerExamination is in progress
Status updated on  01.05.2019
FormerRequest for examination was made
Status updated on  26.01.2018
FormerThe international publication has been made
Status updated on  02.11.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Children's Medical Center Corporation
55 Shattuck Street
Boston, MA 02115 / US
[2018/09]
Inventor(s)01 / WILLIAMS, David A.
169 Centre Street
Dover, Massachusetts 02030 / US
02 / DE VITA, Serena
255 Northampton Street
Unit 501
Boston, Massachusetts 02118 / US
 [2018/09]
Representative(s)Fish & Richardson P.C.
Highlight Business Towers
Mies-van-der-Rohe-Straße 8
80807 München / DE
[N/P]
Former [2018/09]Conroy, John
Fish & Richardson P.C.
Highlight Business Towers
Mies-van-der-Rohe-Straße 8
80807 München / DE
Application number, filing date16783626.115.04.2016
[2018/09]
WO2016US27715
Priority number, dateUS201562152350P24.04.2015         Original published format: US 201562152350 P
[2018/09]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016172001
Date:27.10.2016
Language:EN
[2016/43]
Type: A1 Application with search report 
No.:EP3286184
Date:28.02.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 27.10.2016 takes the place of the publication of the European patent application.
[2018/09]
Type: B1 Patent specification 
No.:EP3286184
Date:25.03.2020
Language:EN
[2020/13]
Search report(s)International search report - published on:KR27.10.2016
(Supplementary) European search report - dispatched on:EP16.08.2018
ClassificationIPC:C07D413/14, C07D413/06, C07D271/10, C07D209/04, A61K31/4245, A61K31/404, A61P29/00, A61P19/00
[2018/09]
CPC:
C07D413/14 (EP,US); A61K31/4245 (EP,US); A61K31/4439 (EP,US);
A61K45/06 (US); A61P19/08 (EP,US); A61P29/00 (EP,US);
A61P35/02 (EP,US); C07D413/06 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/09]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VERBINDUNGEN ZUR BEHANDLUNG VON RAC-GTPASE-VERMITTELTEN ERKRANKUNGEN[2018/09]
English:COMPOUNDS FOR TREATING RAC-GTPASE MEDIATED DISORDER[2018/09]
French:COMPOSÉS POUR LE TRAITEMENT DE TROUBLE INDUIT PAR RAC-GTPASE[2018/09]
Entry into regional phase23.11.2017National basic fee paid 
23.11.2017Search fee paid 
23.11.2017Designation fee(s) paid 
23.11.2017Examination fee paid 
Examination procedure23.11.2017Examination requested  [2018/09]
23.11.2017Date on which the examining division has become responsible
14.03.2019Amendment by applicant (claims and/or description)
06.05.2019Despatch of a communication from the examining division (Time limit: M04)
09.08.2019Reply to a communication from the examining division
17.10.2019Communication of intention to grant the patent
17.02.2020Fee for grant paid
17.02.2020Fee for publishing/printing paid
17.02.2020Receipt of the translation of the claim(s)
Opposition(s)12.01.2021No opposition filed within time limit [2021/11]
Fees paidRenewal fee
27.04.2018Renewal fee patent year 03
29.04.2019Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU15.04.2016
AL25.03.2020
AT25.03.2020
CY25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
ES25.03.2020
FI25.03.2020
HR25.03.2020
IT25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
MK25.03.2020
MT25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
TR25.03.2020
IE15.04.2020
LU15.04.2020
BE30.04.2020
CH30.04.2020
LI30.04.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
[2022/31]
Former [2022/30]HU15.04.2016
AL25.03.2020
AT25.03.2020
CY25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
ES25.03.2020
FI25.03.2020
HR25.03.2020
IT25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
MT25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
TR25.03.2020
IE15.04.2020
LU15.04.2020
BE30.04.2020
CH30.04.2020
LI30.04.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2022/27]HU15.04.2016
AT25.03.2020
CY25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
ES25.03.2020
FI25.03.2020
HR25.03.2020
IT25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
MT25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
TR25.03.2020
IE15.04.2020
LU15.04.2020
BE30.04.2020
CH30.04.2020
LI30.04.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2021/24]AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
ES25.03.2020
FI25.03.2020
HR25.03.2020
IT25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SI25.03.2020
SK25.03.2020
SM25.03.2020
IE15.04.2020
LU15.04.2020
BE30.04.2020
CH30.04.2020
LI30.04.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2021/20]AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
ES25.03.2020
FI25.03.2020
HR25.03.2020
IT25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
IE15.04.2020
LU15.04.2020
BE30.04.2020
CH30.04.2020
LI30.04.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2021/10]AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
ES25.03.2020
FI25.03.2020
HR25.03.2020
IT25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
PL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
LU15.04.2020
BE30.04.2020
CH30.04.2020
LI30.04.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2021/09]AT25.03.2020
CZ25.03.2020
DK25.03.2020
EE25.03.2020
ES25.03.2020
FI25.03.2020
HR25.03.2020
IT25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
LU15.04.2020
CH30.04.2020
LI30.04.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2021/08]CZ25.03.2020
DK25.03.2020
EE25.03.2020
ES25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
LU15.04.2020
CH30.04.2020
LI30.04.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2021/04]CZ25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
MC25.03.2020
NL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2020/50]CZ25.03.2020
EE25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2020/49]CZ25.03.2020
FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SK25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2020/48]FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
RO25.03.2020
RS25.03.2020
SE25.03.2020
SM25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
PT18.08.2020
Former [2020/47]FI25.03.2020
HR25.03.2020
LT25.03.2020
LV25.03.2020
NL25.03.2020
RS25.03.2020
SE25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
Former [2020/46]FI25.03.2020
HR25.03.2020
LV25.03.2020
NL25.03.2020
RS25.03.2020
SE25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
IS25.07.2020
Former [2020/45]FI25.03.2020
HR25.03.2020
LV25.03.2020
NL25.03.2020
RS25.03.2020
SE25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
Former [2020/39]FI25.03.2020
HR25.03.2020
LV25.03.2020
RS25.03.2020
SE25.03.2020
BG25.06.2020
NO25.06.2020
GR26.06.2020
Former [2020/38]FI25.03.2020
HR25.03.2020
LV25.03.2020
RS25.03.2020
SE25.03.2020
NO25.06.2020
GR26.06.2020
Former [2020/37]FI25.03.2020
HR25.03.2020
LV25.03.2020
RS25.03.2020
SE25.03.2020
NO25.06.2020
Former [2020/35]FI25.03.2020
NO25.06.2020
Documents cited:Search  No further relevant documents disclosed
International search[X] WO2014059305  (CHILDRENS MEDICAL CENTER et al.) [X] 1-13, 20 * See abstract; claims 6-13, 40; and page 20, lines 19-21. *
 [A] WO2008086854  (MERCK PATENT GMBH et al.) [A] 1-13, 20 * See abstract; and claims 1, 18. *
 [A] US2012253040  (MASUDA KOJI et al.) [A] 1-13, 20 * See abstract; claim 1; and page 143, example 1. *
 [A] US2010120810  (LEBLOND BERTRAND et al.) [A] 1-13, 20 * See abstract; and claim 1. *
 [A]   WAGNER, E. ET AL.: "Synthesis and pharmacological screening of derivatives of isoxazolo [4,5-d] pyrimidine", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 43, no. 11, 2008, pages 2498 - 2504, XP025571382 [A] 1-13, 20 * See abstract; page 2499, right column; and scheme 1. *

DOI:   http://dx.doi.org/10.1016/j.ejmech.2008.01.035
by applicantWO2014059305
 US2002155166
 US4522811
   ETIENNE-MANNEVILLE, S. ET AL., NATURE, vol. 420, 2002, pages 629 - 635
   BOETTNER, B. ET AL., GENE, vol. 286, 2002, pages 155 - 174
   HALL, A., SCIENCE, vol. 279, 1998, pages 509 - 514
   WENNERBERG, K.DER, C. J., J. CELL SCI., vol. 117, 2004, pages 1301 - 1312
   RIDLEY, A. J., TRENDS CELL BIOL., vol. 16, 2006, pages 522 - 529
   MALUMBRES, M. ET AL., NAT. REV. CANCER, vol. 3, 2003, pages 459 - 465
   GAO, Y. ET AL., PROC. NATL. ACAD. SCI.USA, vol. 101, 2004, pages 7618 - 7623
   QIU, R. G. ET AL., NATURE, vol. 374, 1995, pages 457 - 459
   KHOSRAVI-FAR, R. ET AL., MOL. CELL. BIOL., vol. 15, 1995, pages 6443 - 6453
   RENSHAW, M. W. ET AL., CURR. BIOL., vol. 6, 1996, pages 76 - 83
   FERRARO, D. ET AL., ONCOGENE, vol. 25, 2006, pages 3689 - 3698
   HWANG, S. L. ET AL., J. CLIN. NEUROSCI., vol. 12, 2005, pages 571 - 574
   KARNOUB, A. E. ET AL., BREAST CANCER RES. TREAT., vol. 84, 2004, pages 61 - 71
   MIZUKAWA B. ET AL., BLOOD, vol. 118, 2011, pages 5235 - 45
   E K THOMAS ET AL., LEUKEMIA, vol. 22, May 2008 (2008-05-01), pages 898 - 904
   MURRAY ET AL., PNAS, vol. 107, no. 20, 2010, pages 9446 - 9451
   GERARD ET AL., ACS COMB. SCI., vol. 13, 2011, pages 365
   T. W. GREENEP. G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY & SONS, INC.
   "Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY, pages: 1418
   JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 2
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.